<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03713879</url>
  </required_header>
  <id_info>
    <org_study_id>StentvsNSAID</org_study_id>
    <nct_id>NCT03713879</nct_id>
  </id_info>
  <brief_title>Comparative Effectiveness Between Indomethacin and Pancreatic Stenting in the Prevention of Post ERCP Pancreatitis</brief_title>
  <official_title>Comparative Effectiveness Between Rectally Administered Indomethacin and Pancreatic Stenting in the Prevention of Post Endoscopic Retrograde Cholangio-panceaticography (ERCP) Pancreatitis: a Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Union Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eastern Hepatobiliary Surgery Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post ERCP pancreatitis (PEP) occurs in 4 to 5% of patients and is associated with significant
      morbidities and occasional mortalities. The use of rectall administered indomethacin and
      pancreatic duct stent (PDS) placement have independently been proven to reduce PEP. The
      comparative effectiveness of the two methods has however not been studied. It is argued that
      in the context of indomethacin, the placement of a PDS is unnecessary. Advocates for PDS
      insertion however believe that mechanical decompression of the pancreatic duct is critical in
      the prevention of pancreatitis. The investigators propose a multi-centre randomised
      controlled trial to compare the use of rectal indomethacin to PDS insertion in high risk
      patients in the prevention of PEP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background of research

      Pancreatitis is the most common complication after Endoscopic retrograde
      cholangiopancreatography (ERCP). It occurs in approximately 5% of patients. The risk can
      approach 20 to 30% in those with known pre- and intra-procedural risk factors. Three in 100
      patients with post ERCP pancreatitis (PEP) consequently die. The placement of pancreatic duct
      stent and the use of rectal administered indomethacin have both been independently shown to
      reduce PEP. The placement of a pancreatic duct stent has been for a long time considered the
      gold standard in the prophylaxis against PEP. In a meta-analysis of 8 RCTs that compared the
      use of pancreatic duct stents to no treatment, pancreatic duct stenting in high risk patients
      reduces incidence of PEP by approximately 5 fold. In a landmark study by Elmunzer et al.,
      rectal administered indomethacin was shown to reduce PEP (52 of 307 patients,16.9% to 27 of
      295 patients, 9.2%, P=0.005). In the trial, &gt;80% received pancreatic duct stents in addition
      to rectal indomethacin. Overall there have been 7 RCTs on the use of rectal indomethacin all
      showing benefits with its use, 3 with PDS and 4 without. In the literature, there has been no
      direct comparison between the use of rectal indomethacin alone and insertion of PDS. In a
      secondary analysis of the trial by Elmunzer et al., PEP following the use of rectal
      indomethacin alone was less compared with the placement of PDS. In a meta-analysis by Akbar
      et al. pooling 29 studies (22 PDS and 7 indomethacin), the use of rectal indomethacin alone
      was associated with fewer PEP when compared to insertion of PDS on an indirect comparison
      using network metaanalysis (OR 0.48, 95%CI 0.26-0.87). The more favorable results with rectal
      indomethacin alone raised the question if PDS insertion is necessary. Furthermore, in another
      secondary analysis, patients after failed PDS insertion had a 34.7% rate of pancreatitis. In
      contrary, the rate of pancreatitis was 16.4% in those after successful PDS and 12.1% after no
      attempt at PDS insertion. The SVI (stent versus indomethacin) trial (NCT024762279) by the US
      cooperative for Outcomes Research in Endoscopy (USCORE) group is an ongoing non-inferiority
      trial that compares indomethacin alone to the combination of indomethacin and PDS in 1430
      high risk patients with the primary outcome of pancreatitis. The trial tests the hypothesis
      that PDS is no longer necessary in the context of rectal indomethacin.

      The rationale for the trial has been based on the secondary analysis of the Elmunzer trial
      and the network analysis aforementioned.

      The investigators argue that the relative merits of rectal indomethacin and PDS placement
      have not been established. There may have been substantial difference in the baseline risks
      between the trials using either rectal indomethacin and PDS placement alone. The small number
      of RCTs over the use of rectal indomethacin may have overestimated its beneficial effect
      especially among patients at lower risk of PEP. A direct comparison in the form of a RCT to
      compare effectiveness of both treatment modalities is required. The insertion of PDS may
      continue to be important in patients contraindicated for the use of NSAIDs.

      Research plan and methodology The investigators hypothesize that rectal administration of
      indomethacin is not inferior to placement of a pancreatic duct stent in the prevention of
      pancreatitis after ERCP in high risk patients. In patients randomised to receive pancreatic
      duct stents, the investigators sought to determine the success rate with PDS insertion and
      outcomes following successful or unsuccessful PDS insertion. In addition, the investigators
      analyse possible factors to PEP in both cohorts of patients on either indomethacin or PDS.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 21, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>rectal indomethacin 100 mg to be administered before or after ERCP
a PD stent to be inserted during ERCP (a 3 to 5 cm 5Fr single pigtail pancreatic duct stent without inner flap is used, the stent is inserted after deep cannulation of pancreatic duct with a .025&quot; or .035&quot; wire) or
a PD stent plus rectal indomethacin 100 mg before or after ERCP
In patients randomized to receive PD stenting, the number of attemtps is limited to 5.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>post-ERCP pancreatitis</measure>
    <time_frame>30 days</time_frame>
    <description>Percentage of Participants with post ERCP pancreatitis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>high severity of post-ERCP pancreatitis</measure>
    <time_frame>30 days</time_frame>
    <description>Percentage of Participants with high severity of post-ERCP pancreatitis using the Clavian-Dindo classification
(1 / 2 / 3 / 3a / 3b / 4 / 4a/ 4b / 5)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pancreatitis with complications</measure>
    <time_frame>30 days</time_frame>
    <description>Percentage of Participants with pancreatitis with complications using Atlanta classification (Mild / Moderate / Severe / Critical )</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>hospital stay</measure>
    <time_frame>30 days</time_frame>
    <description>period of hospitalisation (days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>endoscopic intervention due to PEP</measure>
    <time_frame>30 days</time_frame>
    <description>Percentage of Participants with endoscopic intervention due to Post ERCP pancreatitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>radiologic intervention due to PEP</measure>
    <time_frame>30 days</time_frame>
    <description>Percentage of Participants with radiologic intervention due to Post ERCP pancreatitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>surgery due to PEP</measure>
    <time_frame>30 days</time_frame>
    <description>Percentage of Participants with Surgical intervention due to Post ERCP pancreatitis</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1734</enrollment>
  <condition>Post ERCP Pancreatitis</condition>
  <arm_group>
    <arm_group_label>indomethacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rectal indomethacin 100 mg to be administered before or after ERCP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pancreatic stenting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>a PD stent to be inserted during ERCP (a 3 to 5 cm 5Fr single pigtail pancreatic duct stent without inner flap is used, the stent is inserted after deep cannulation of pancreatic duct with a .025&quot; or .035&quot; wire)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>indomethacin plus pancreatic stenting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>[rectal indomethacin 100 mg to be administered before or after ERCP] plus [a PD stent to be inserted during ERCP (a 3 to 5 cm 5Fr single pigtail pancreatic duct stent without inner flap is used, the stent is inserted after deep cannulation of pancreatic duct with a .025&quot; or .035&quot; wire]</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>pancreatic stenting</intervention_name>
    <description>a PD stent to be inserted during ERCP (a 3 to 5 cm 5Fr single pigtail pancreatic duct stent without inner flap is used, the stent is inserted after deep cannulation of pancreatic duct with a .025&quot; or .035&quot; wire)</description>
    <arm_group_label>indomethacin plus pancreatic stenting</arm_group_label>
    <arm_group_label>pancreatic stenting</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indomethacin</intervention_name>
    <description>rectally administered indomethacin before or after ERCP</description>
    <arm_group_label>indomethacin</arm_group_label>
    <arm_group_label>indomethacin plus pancreatic stenting</arm_group_label>
    <other_name>indocid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        presence of one of the following risk factors for Post ERCP Pancreatitis

          1. sphincter of Oddi dysfunction

          2. history of PEP, pancreatic instrumentation or sphincterotomy, precut sphincterotomy,

          3. difficult cannulation defined by &gt;5 cannulation attempts

          4. the use of double wire technique in bile duct access

          5. at least 2 of the followings including i) female age&lt;50 ii) 3 pancreatograms iii)
             acinarization (contrast injection to tail fo pancreas). iv） normal bilirubin；
             v）guidewire to the tail of pancreas or secondary branches.

        Exclusion Criteria:

          -  patients intended for pancreatic stenting e.g. those with pancreatic duct strictures,
             ampullectomy,

          -  without informed consents from patient or next of kin

          -  age &lt;18

          -  pregnant or lactating women

          -  patients with altered anatomy except except Billroth I and II gastrectomy

          -  contraindications to the use of NSAIDs such as those with active gastrointestinal
             bleeding, renal failure (serum creatinine &gt; 140)

          -  known NSAID allergy

          -  incipient heart failure.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James LAU, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>James LAU, MD</last_name>
    <phone>35051411</phone>
    <email>laujyw@surgery.cuhk.edu.hk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>RAYMOND TANG, MD</last_name>
    <phone>35052640</phone>
    <email>raymondtang@cuhk.edu.hk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Endoscopy centre</name>
      <address>
        <city>Xi'an</city>
        <state>Shan XI</state>
        <zip>710000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yang Lin Pan, MD</last_name>
      <email>panyl@fmmu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Pang Yang Lin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kai Chun Wu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eastern Hepatobiliary Surgery Hospital,Endoscopy centre</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bing HU, MD</last_name>
      <email>drhubing@aliyun.com</email>
    </contact>
    <investigator>
      <last_name>Bing Hu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Endoscopy centre</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yu Bai, MD</last_name>
      <email>baiyu1998@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>YU Bai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Endoscopy centre</name>
      <address>
        <city>Tianjin</city>
        <state>Tian Jin</state>
        <zip>300000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wen Li, MD</last_name>
      <email>drliwen@126.com</email>
    </contact>
    <investigator>
      <last_name>Wen Li, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Endoscopy centre</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yun Sheng Qing, MD</last_name>
      <email>175260446@qq.com</email>
    </contact>
    <investigator>
      <last_name>Yun sheng Qing, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Endoscopy Centre, Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Y LAU, Prof</last_name>
      <phone>+85235051411</phone>
      <email>laujyw@surgery.cuhk.edu.hk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>2. Chulalongkorn University and King Chulalongkorn Memorial Hospital</name>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Supakarn Chaithongrat, MD</last_name>
      <email>pangicu@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Parit Mekaroonkamol, MD</last_name>
      <email>parit_m@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
    <country>Hong Kong</country>
    <country>Thailand</country>
  </location_countries>
  <reference>
    <citation>Andriulli A, Loperfido S, Napolitano G, Niro G, Valvano MR, Spirito F, Pilotto A, Forlano R. Incidence rates of post-ERCP complications: a systematic survey of prospective studies. Am J Gastroenterol. 2007 Aug;102(8):1781-8. Epub 2007 May 17. Review.</citation>
    <PMID>17509029</PMID>
  </reference>
  <reference>
    <citation>Choudhary A, Bechtold ML, Arif M, Szary NM, Puli SR, Othman MO, Pais WP, Antillon MR, Roy PK. Pancreatic stents for prophylaxis against post-ERCP pancreatitis: a meta-analysis and systematic review. Gastrointest Endosc. 2011 Feb;73(2):275-82. doi: 10.1016/j.gie.2010.10.039. Review.</citation>
    <PMID>21295641</PMID>
  </reference>
  <reference>
    <citation>Elmunzer BJ, Scheiman JM, Lehman GA, Chak A, Mosler P, Higgins PD, Hayward RA, Romagnuolo J, Elta GH, Sherman S, Waljee AK, Repaka A, Atkinson MR, Cote GA, Kwon RS, McHenry L, Piraka CR, Wamsteker EJ, Watkins JL, Korsnes SJ, Schmidt SE, Turner SM, Nicholson S, Fogel EL; U.S. Cooperative for Outcomes Research in Endoscopy (USCORE). A randomized trial of rectal indomethacin to prevent post-ERCP pancreatitis. N Engl J Med. 2012 Apr 12;366(15):1414-22. doi: 10.1056/NEJMoa1111103.</citation>
    <PMID>22494121</PMID>
  </reference>
  <reference>
    <citation>Murray B, Carter R, Imrie C, Evans S, O'Suilleabhain C. Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. Gastroenterology. 2003 Jun;124(7):1786-91.</citation>
    <PMID>12806612</PMID>
  </reference>
  <reference>
    <citation>Khoshbaten M, Khorram H, Madad L, Ehsani Ardakani MJ, Farzin H, Zali MR. Role of diclofenac in reducing post-endoscopic retrograde cholangiopancreatography pancreatitis. J Gastroenterol Hepatol. 2008 Jul;23(7 Pt 2):e11-6. Epub 2007 Aug 7.</citation>
    <PMID>17683501</PMID>
  </reference>
  <reference>
    <citation>Montaño Loza A, Rodríguez Lomelí X, García Correa JE, Dávalos Cobián C, Cervantes Guevara G, Medrano Muñoz F, Fuentes Orozco C, González Ojeda A. [Effect of the administration of rectal indomethacin on amylase serum levels after endoscopic retrograde cholangiopancreatography, and its impact on the development of secondary pancreatitis episodes]. Rev Esp Enferm Dig. 2007 Jun;99(6):330-6. Spanish.</citation>
    <PMID>17883296</PMID>
  </reference>
  <reference>
    <citation>Otsuka T, Kawazoe S, Nakashita S, Kamachi S, Oeda S, Sumida C, Akiyama T, Ario K, Fujimoto M, Tabuchi M, Noda T. Low-dose rectal diclofenac for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a randomized controlled trial. J Gastroenterol. 2012 Aug;47(8):912-7. doi: 10.1007/s00535-012-0554-7. Epub 2012 Feb 18.</citation>
    <PMID>22350703</PMID>
  </reference>
  <reference>
    <citation>Katsinelos P, Fasoulas K, Paroutoglou G, Chatzimavroudis G, Beltsis A, Terzoudis S, Katsinelos T, Dimou E, Zavos C, Kaltsa A, Kountouras J. Combination of diclofenac plus somatostatin in the prevention of post-ERCP pancreatitis: a randomized, double-blind, placebo-controlled trial. Endoscopy. 2012 Jan;44(1):53-9. doi: 10.1055/s-0031-1291440. Epub 2011 Dec 23.</citation>
    <PMID>22198776</PMID>
  </reference>
  <reference>
    <citation>Sotoudehmanesh R, Khatibian M, Kolahdoozan S, Ainechi S, Malboosbaf R, Nouraie M. Indomethacin may reduce the incidence and severity of acute pancreatitis after ERCP. Am J Gastroenterol. 2007 May;102(5):978-83. Epub 2007 Mar 13.</citation>
    <PMID>17355281</PMID>
  </reference>
  <reference>
    <citation>Elmunzer BJ, Higgins PD, Saini SD, Scheiman JM, Parker RA, Chak A, Romagnuolo J, Mosler P, Hayward RA, Elta GH, Korsnes SJ, Schmidt SE, Sherman S, Lehman GA, Fogel EL; United States Cooperative for Outcomes Research in Endoscopy. Does rectal indomethacin eliminate the need for prophylactic pancreatic stent placement in patients undergoing high-risk ERCP? Post hoc efficacy and cost-benefit analyses using prospective clinical trial data. Am J Gastroenterol. 2013 Mar;108(3):410-5. doi: 10.1038/ajg.2012.442. Epub 2013 Jan 8.</citation>
    <PMID>23295278</PMID>
  </reference>
  <reference>
    <citation>Akbar A, Abu Dayyeh BK, Baron TH, Wang Z, Altayar O, Murad MH. Rectal nonsteroidal anti-inflammatory drugs are superior to pancreatic duct stents in preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a network meta-analysis. Clin Gastroenterol Hepatol. 2013 Jul;11(7):778-83. doi: 10.1016/j.cgh.2012.12.043. Epub 2013 Jan 30. Review.</citation>
    <PMID>23376320</PMID>
  </reference>
  <reference>
    <citation>Choksi NS, Fogel EL, Cote GA, Romagnuolo J, Elta GH, Scheiman JM, Chak A, Mosler P, Higgins PD, Korsnes SJ, Schmidt SE, Sherman S, Lehman GA, Elmunzer BJ; United States Cooperative for Outcomes Research in Endoscopy. The risk of post-ERCP pancreatitis and the protective effect of rectal indomethacin in cases of attempted but unsuccessful prophylactic pancreatic stent placement. Gastrointest Endosc. 2015 Jan;81(1):150-5. doi: 10.1016/j.gie.2014.07.033.</citation>
    <PMID>25527053</PMID>
  </reference>
  <reference>
    <citation>Cotton PB, Lehman G, Vennes J, Geenen JE, Russell RC, Meyers WC, Liguory C, Nickl N. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc. 1991 May-Jun;37(3):383-93. Review.</citation>
    <PMID>2070995</PMID>
  </reference>
  <reference>
    <citation>Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibañes E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009 Aug;250(2):187-96. doi: 10.1097/SLA.0b013e3181b13ca2.</citation>
    <PMID>19638912</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>August 23, 2018</study_first_submitted>
  <study_first_submitted_qc>October 18, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2018</study_first_posted>
  <last_update_submitted>May 28, 2020</last_update_submitted>
  <last_update_submitted_qc>May 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>James Yun-wong Lau</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>post ERCP panceatitis</keyword>
  <keyword>rectal indomethacin</keyword>
  <keyword>pancreatic stents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Indomethacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

